Cardiovascular medical device developer PLC Systems unveiled its RenalGuard system at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., this week.
RenalGuard is an investigational system and therapy that targets patients with compromised renal function who may be at risk for contrast-induced nephropathy (CIN) when undergoing cardiovascular imaging procedures. It is a fully-automated, real-time matched, fluid-replacement device intended for the at-risk segment of interventional cardiology and radiology patients undergoing imaging procedures.
Earlier this year, the company announced the successful enrollment of the first patients in its FDA-approved pilot clinical trial designed to evaluate the safety of its RenalGuard System. Safety results were favorable, and there were no adverse renal events related to the device recorded, according to the Franklin, Mass.-based firm.